In serum-free cultures, CML iCD34+ cells were able to withstand growth factor deprivation in both CD38+ and CD38− compartments, which was reversed by treatment with imatinib (Fig. 2d). The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.